低分子肝素在阿替普酶溶栓治疗中的应用
Clinical Study of Low Molecular Weight Heparin Combined with Alteplase for Thrombolysis
-
摘要: [摘要]目的 探讨急性心肌梗死(acute myocardial infarction,AMI)低分子肝素在阿替普酶(Alteplase,rt-PA)溶栓治疗的应用,并与溶栓治疗中传统抗凝药物普通肝素相比较.方法 选取AMI患者35例,其中研究组15例,对照组20例,均给予阿替普酶静脉溶栓治疗;研究组溶栓前即刻静脉注射依诺肝素素30 mg,溶栓后15 min皮下注射依诺肝素40 mg,以后每12 h皮下注射依诺肝素40 mg,共5 d;对照组:溶栓前即刻静脉注射普通肝素4 000 U(或 60 U/kg),后以800~1 000 U/h 静脉泵入普通肝素,依据部分凝血活酶时间(APTT值)调整肝素用量,每3 h测一次凝血常规,使APTT维持于正常对照的1.5~2.0倍(50~70 s),48 h后改为皮下注射依诺肝素每12 h 40 mg,共5 d.所有患者均给予指南推荐的常规治疗.结果 研究组达到临床再通及冠脉再通标准为86.66%,再通时间平均(1.62±0.36)h;对照组为65.00%,再通时间(1.81±0.33)h.2组再通率及再通时间比较差异无统计学意义(P>0.05).出血并发症研究组1例(6.66%),对照组5例(25%),2组均未出现颅内出血等严重或致命性出血.结论 急性心肌梗死使用阿替普酶溶栓治疗中抗凝药物选用低分子肝素疗效不低于传统普通肝素,但方法简便、操作简化,不必反复监测凝血指标,减轻了临床工作负担,优化了溶栓流程,适合向基层及急救系统推广应用.
-
关键词:
- [关键词]急性心肌梗死 /
- 低分子肝素 /
- 静脉溶栓疗法
Abstract: [Abstract]Objective The aim of this study was to investigate the application of low molecular weight heparin combined with alteplase for thrombolysis in patients with acute myocardial infarction(AMI),and to compare its thrombolysis effect with traditional anticoagulant-general heparin. Methods 35 AMI patients with alteplase intravenous thrombolytic therapy were divided into two groups,among which 15 cases in the study group were treated with 30 mg enoxaparin instant intravenous injection before thrombolysis,40 mg enoxaparin hypodermic injection 15 minutes after thrombolysis,40 mg enoxaparin hypodermic injection every 12 hours for 5 days. The other 20 cases were assigned to the control group and treated with 4 000 u(or 60 u/kg)general heparin instant intravenous injection,then pumped general heparin intravenously in the rate of 800-1 000 u/h. Meanwhile, detected coagulation convention every 3 hours and adjusted the dose of heparin according to the activated partial thromboplastin time(APTT)to keep APTT value within 1.5 to 2.0 times (50-70 s) the standard value. 48 hours later, patients in the control group was given hypodermic injection of 40 mg enoxaparin every 12 hours for 5 days. All cases were given regular treatment as guidelines recommended. Results The patency rate of infarct-related coronary artery assessed by unified clinical criteria was 86.66% and 65.00%, and the average recanalization time was(1.62±0.36)h and (1.81±0.33)h in the study and control groups, respectively. There were no significant differences on patency rate and recanalization time between the two groups(P > 0.05). One case of bleeding complication occurred in the study group(6.66%),while five cases occurred in the control group(25.00%). In the two groups,no cases appeared intracranial hemorrhage and other serious or fatal bleeding occurred. Conclusion The clinical efficacy of low molecular weight heparin was non-inferior to general heparin in AMI patients with alteplas thrombolysis. The application of low molecular weight heparin was simple and easy to operate. It can optimize the procedure of thrombolysis,reduce repetitive coagulation index monitoring and lessen clinical workload,which is worth being promoted to primary hospital and the emergency systems. 期刊类型引用(11)
1. 薛占成,韩海燕,刘冀琴,周秀. 机化性肺炎患者T淋巴细胞亚群分析的临床意义. 实用检验医师杂志. 2023(02): 185-188 . 百度学术
2. 付春芳,赵鑫. 肺结核患者检测免疫功能指标及血清PCT、PA的临床意义探讨. 中国实用医药. 2022(10): 104-106 . 百度学术
3. 郑树斌,陈天杨,陈欣羽,刘孟珂. 肺泡灌洗液中T淋巴细胞亚群水平对于肺结核诊断和疗效判断的Meta分析. 临床医学研究与实践. 2021(01): 15-18+22 . 百度学术
4. 何晗,唐柳生,李世立,董捷,周游,韦显珍. 青年肺结核患者支气管肺泡灌洗液T淋巴细胞亚群及炎症因子测定价值分析. 右江医学. 2020(09): 686-690 . 百度学术
5. 吴雪琼. 淋巴细胞亚群检测及对结核病诊断和患者免疫状况评价的价值. 中国防痨杂志. 2020(10): 1020-1024 . 百度学术
6. 冯睿婷,赵继智. 肺结核患者血清T淋巴细胞亚群检测流式细胞术的应用. 内蒙古医学杂志. 2020(10): 1190-1191 . 百度学术
7. 张丽柯,杨卫,史芳瑜,徐全晓. 流式细胞仪淋巴亚群在肿瘤化学治疗后患者中的应用效果. 实用医技杂志. 2019(04): 445-447 . 百度学术
8. 庞凡,仲燕,刘雅. 肺结节病患者支气管肺泡灌洗液及外周血中T淋巴细胞亚群水平检测的意义. 检验医学与临床. 2019(20): 3013-3015 . 百度学术
9. 杨秀丽. 化疗联合艾迪注射液对晚期肺癌患者瘤体变化及免疫功能的影响. 中国中医基础医学杂志. 2018(02): 222-225 . 百度学术
10. 李昱,杨庚. 白细胞介素12对耐药结核大鼠模型的影响. 中国医药生物技术. 2018(01): 54-58 . 百度学术
11. 李芹,张静. 肺结节病患者T淋巴细胞亚群检测的诊断价值. 宁夏医学杂志. 2018(10): 944-945 . 百度学术
其他类型引用(3)
-

计量
- 文章访问数: 2249
- HTML全文浏览量: 714
- PDF下载量: 205
- 被引次数: 14